Juvenile hypertension

Česká verzia

Authors: M. Vícha; J. Václavík
Authors place of work: I. interní klinika – kardiologická LF UP a FN Olomouc
Published in the journal: Kardiol Rev Int Med 2018, 20(2): 104-108

Summary

Arterial hypertension is one of the most common cardiovascular diseases in clinical practice. The diagnosis and therapy of young patients have their specifics due to a more common occurrence of secondary forms of hypertension. Specifically, it is very important to think of false isolated systolic hypertension in young men. All classes of antihypertensive drugs are suitable for the initiation and maintenance of antihypertensive treatment, but interactions and contra-indications need to be respected. Despite some exceptions, the target blood pressure at outpatient visits is less than 140/90 mmHg.

Key words:
juvenile hypertension – arterial hypertension – blood pressure – secondary hypertension – isolated systolic hypertension – pharmacotherapy – guidelines –treatment

Zdroje

1. ESH/ ESC Task Force for the Management of Arterial Hypertension. 2013 Practice Guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC): ESH/ ESC Task Force for the Management of Arterial Hypertension. J Hypertens 2013; 31(10): 1925– 1938. doi: 10.1097/ HJH.0b013e328364ca4c.

2. Táborský M, Kautzner J, Linhart A et al. Kardiologie. Praha: Mladá fronta 2017.

3. Cífková R, Bruthans J, Adámková V et al. Prevalence základních kardiovaskulárních rizikových faktorů v české populaci v letech 2006– 2009. Studie Czech post-MONICA. Cor Vasa 2011; 53: 220– 229.

4. Hansen ML, Gunn PW, Kaelber DC. Underdiagnosis of hypertension in children and adolescents. JAMA 2007; 298(8): 874– 879. doi: 10.1001/ jama.298.8.874.

5. Kaelber DC, Liu W, Ross M et al. Comparative Effectiveness Research Through Collaborative Electronic Reporting (CER2) Consortium. Diagnosis and medication treatment of pediatric hypertension: a retrospective cohort study. Pediatrics 2016; 138(6): e20162195. doi: 10.1542/ peds.2016-2195.

6. Widimský J jr, Filipovský J, Ceral J et al. Doporučení pro diagnostiku a léčbu arteriální hypertenze 2017. Hypertenze a kardiovaskulární prevence 2018; 7 (Suppl): 1– 19.

7. Šamánek M, Urbanová Z, Reich O et al. Doporučení pro diagnostiku a léčbu hypertenze v dětství a dospívání. Cor Vasa 2009; 51(3): 227– 235.

8. Carretero OA, Oparil S. Essential hypertension. Circulation 2000; 101(3): 329– 335.

9. Viera A, Neutze D. Diagnosis of secondary hypertension: an age-based approach. Am Fam Physician 2010; 82(12): 1471– 1478.

10. Václavík J. Obtížně léčitelná hypertenze. 2. vyd. Praha: Mladá fronta 2017.

11. Zelinka T, Widimský J jr, Ceral J et al. Jak postupovat při podezření na sekundární arteriální hypertenzi. Hypertenze a kardiovaskulární prevence. Dostupné na: http:/ / www.hypertension.cz.

12. Brojendra A et al. Clinical manifestations and diagnosis of coarctation of the aorta. In: UpToDate.com. Available at: https:/ / www.uptodate.com/ contents/ clinical-manifestations-and-diagnosis-of-coarctation-of-the-aorta.

13. D'Souza SJ, Tsai WS, Silver MM et al. Diagnosis and management of stenotic aorto-arteriopathy in childhood. J Pediatr 1998; 132(6): 1016– 1022.

14. Olin JW, Froehlich J, Gu X et al. The United States registry for fibromuscular dysplasia: results in the first 447 patients. Circulation 2012; 125(25): 3182– 3190. doi: 10.1161/ CIRCULATIONAHA.112.091223.

15. Green R, Gu X, Kline-Rogers E et al. Differences between the pediatric and adult presentation of fibromuscular dysplasia: results from the US Registry. Pediatr Nephrol 2016; 31(4): 641– 650. doi: 10.1007/ s00467-015-3234-z.

16. Olin JW. Clinical manifestations and diagnosis of fibromuscular dysplasia. UpToDate.com. Available at: https:/ / www.uptodate.com/ contents/ clinical-manifestations-and-diagnosis-of-fibromuscular-dysplasia .

17. Fommei E, Iervasi G. The role of thyroid hormone in blood pressure homeostasis: evidence from short-term hypothyroidism in humans. J Clin Endocrinol Metab 2002; 87(5): 1996– 2000. doi: 10.1210/ jcem.87.5.8464.

18. Sharp RP, Gales BJ. Nebivolol versus other beta blockers in patients with hypertension and erectile dysfunction. Ther Adv Urol 2017; 9(2): 59– 63. doi: 10.1177/ 1756287216685027.

19. Makani H, Bangalore S, Romero J et al. Peripheral edema associated with calcium channel blockers: incidence and withdrawal rate - a meta-analysis of randomized trials. J Hypertens 2011; 29(7): 1270– 1280. doi: 10.1097/ HJH.0b013e3283472643.

20. O'Rourke MF, Adji A. Guidelines on guidelines: focus on isolated systolic hypertension in youth. J Hypertens 2013; 31(4): 649– 654. doi: 10.1097/ HJH.0b013e32835d8230.

21. J. Špác. Centrální krevní tlak: jak zlepšit měření krevního tlaku ve 2. století po Korotkovovi. Kardiol Rev Int Med 2008; 10(1): 26– 30.

22. Táborský M et al. Kardiologie pro interní praxi. Praha: Mladá fronta 2014.